A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma

Trial Profile

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Erlotinib (Primary) ; Capecitabine; Fluorouracil; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 May 2018 Planned number of patients changed from 950 to 545.
    • 06 Jun 2017 Primary endpoint of overall survival (phase II portion) has not been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top